相关实验视频

Updated: Jul 31, 2026

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

专家一致认为,Ormutivimab注射用于对抗狂犬病病毒的临床应用

Ruifeng Chen¹, Hu Li², Wuyang Zhu³

¹Department of Emergency Medicine, The Sixth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China.

Expert opinion on drug safety

|July 10, 2023

概括

这一共识为Ormutivimab在狂犬病暴露后预防中的使用提供了指导方针. 它标准化了治疗,改善了结果,并降低了中国的感染率.

科学领域:

免疫学免疫学免疫学
病毒学病毒学
公共卫生公共卫生

背景情况:

没有现有的针对狂犬病使用单克隆抗体 (mAb) 的指导方针.
狂犬病预防和控制专家召开会议,以建立共识.

研究的目的:

为了标准化Ormutivimab在狂犬病后暴露预防 (PEP) 的临床应用.
改善中国的狂犬病预防策略.

主要方法:

专家组制定共识建议的建议.
对于Ormutivimab的使用,定义了特定的暴露分类 (II类,III类).
提供了剂量和使用指南,包括稀释和最大剂量建议.

主要成果:

奥尔穆蒂维马布适用于特定的狂犬病暴露类型,包括免疫缺陷个体.
建议涵盖伤口透,剂量调整和所有年龄组的安全使用.
奥尔穆提维马布已被证明是安全有效的使用,没有任何禁忌.

结论:

标准化临床使用Ormutivimab.
在中国改善了对狂犬病的暴露后预防.
降低了狂犬病感染率.

关键词:

抗狂犬病单克隆抗体抗狂犬病单克隆抗体临床应用临床应用在中国,共识成为标准.或是变动的imab.暴露后预防暴露后预防狂犬病是一种狂犬病.

更多相关视频

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Published on: June 29, 2020

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

相关概念视频

Rabies

Rabies

Rabies is a lethal zoonotic disease caused by a single-stranded, negative-sense RNA virus of the Lyssavirus genus, within the family Rhabdoviridae. Its primary mode of transmission to humans is through bites or saliva-contaminated scratches from infected mammals such as dogs, bats, raccoons, or foxes. Transmission can also occur if infectious saliva contacts abraded skin or intact mucous membranes, including the conjunctiva.Viral Entry and Early ReplicationOnce introduced at the bite or scratch...